This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by THASE, M. E.
Right arrow Articles by RUDOLPH, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by THASE, M. E.
Right arrow Articles by RUDOLPH, R. L.
The British Journal of Psychiatry (2001) 178: 234-241
© 2001 The Royal College of Psychiatrists

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

MICHAEL E. THASE, MD

University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA

A. RICHARD ENTSUAH, PhD and RICHARD L. RUDOLPH, MD

Clinical Research and Development, Wyeth-Ayerst Research, Philadelphia, PA, USA

Correspondence: Michael E. Thase, Professor of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213-2593, USA

Declaration of interest M.E.T. is a paid consultant to Wyeth-Ayerst Laboratories, the employer of A.R.E. and R.L.R.

Background It had been suggested that the antidepressant venlafaxine, which inhibits reuptake of both serotonin and (at higher doses) noradrenaline, may result in better outcomes than treatment with selective serotonin reuptake inhibitors (SSRIs).

Aims To compare remission rates during treatment with SSRIs or venlafaxine.

Method Data from eight comparable randomised, double-blind studies of major depressive disorder were pooled to compare remission rates (Hamilton Rating Scale for Depression score <=7) during treatment with venlafaxine (n=851), SSRIs (fluoxetine, paroxetine, fluvoxamine; n=748) or placebo (four studies; n=446).

Results Remission rates were: venlafaxine, 45% (382/851); SSRIs, 35% (260/748); placebo, 25% (110/446) (P < 0.001; odds ratio for remission is 1.50 (1.3-1.9), favouring venlafaxine v. SSRIs). The difference between venlafaxine and the SSRIs was significant at week 2, whereas the difference between SSRIs and placebo reached significance at week 4. Results were not dependent on any one study or the definition of remission.

Conclusions Remission rates were significantly higher with venlafaxine than with an SSRI.




This article has been cited by other articles:


Home page
 Evid. Based Ment. HealthHome page
C. Barbui, A. Cipriani, T. A Furukawa, G. Salanti, J. P T Higgins, R. Churchill, N. Watanabe, A. Nakagawa, I. M Omori, and J. R Geddes
Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?
Evid. Based Ment. Health, November 1, 2009; 12(4): 101 - 104.
[Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
G. S. Alexopoulos, C. F. Reynolds III, M. L. Bruce, I. R. Katz, P. J. Raue, B. H. Mulsant, D. W. Oslin, T. Ten Have, and The PROSPECT Group
Reducing Suicidal Ideation and Depression in Older Primary Care Patients: 24-Month Outcomes of the PROSPECT Study
Am J Psychiatry, August 1, 2009; 166(8): 882 - 890.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
W. van den Broek, P. Mulder, E van Os, T. Birkenhager, E Pluijms, and J. Bruijn
Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis
J Psychopharmacol, August 1, 2009; 23(6): 708 - 713.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
V Peritogiannis, K Antoniou, V Mouka, V Mavreas, and T. Hyphantis
Duloxetine-induced hypomania: case report and brief review of the literature on SNRIs-induced mood switching
J Psychopharmacol, July 1, 2009; 23(5): 592 - 596.
[Abstract] [PDF]

Home page
 Br. J. PsychiatryHome page
P. Huezo-Diaz, R. Uher, R. Smith, M. Rietschel, N. Henigsberg, A. Marusic, O. Mors, W. Maier, J. Hauser, D. Souery, et al.
Moderation of antidepressant response by the serotonin transporter gene
The British Journal of Psychiatry, July 1, 2009; 195(1): 30 - 38.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
G. Gartlehner, B. N. Gaynes, R. A. Hansen, P. Thieda, A. DeVeaugh-Geiss, E. E. Krebs, C. G. Moore, L. Morgan, and K. N. Lohr
Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians
Ann Intern Med, November 18, 2008; 149(10): 734 - 750.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
G. Papakostas, C. Homberger, and M. Fava
A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
J Psychopharmacol, November 1, 2008; 22(8): 843 - 848.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. A Sopko Jr, M. J Ehret, and M. Grgas
Desvenlafaxine: Another "Me Too" Drug?
Ann. Pharmacother., October 1, 2008; 42(10): 1439 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A Vanoli, C. Lane, C. Harrison, N. Steen, and A. Young
Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications
J Psychopharmacol, June 1, 2008; 22(4): 434 - 440.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
I. Anderson, I. Ferrier, R. Baldwin, P. Cowen, L Howard, G Lewis, K Matthews, R. McAllister-Williams, R. Peveler, J Scott, et al.
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
J Psychopharmacol, June 1, 2008; 22(4): 343 - 396.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
P. Gareri, P. De Fazio, L. Gallelli, S. De Fazio, A. Davoli, G. Seminara, A. Cotroneo, and G. De Sarro
Venlafaxine-Propafenone Interaction Resulting in Hallucinations and Psychomotor Agitation
Ann. Pharmacother., March 1, 2008; 42(3): 434 - 438.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. Brent, G. Emslie, G. Clarke, K. D. Wagner, J. R. Asarnow, M. Keller, B. Vitiello, L. Ritz, S. Iyengar, K. Abebe, et al.
Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression: The TORDIA Randomized Controlled Trial
JAMA, February 27, 2008; 299(8): 901 - 913.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
D. Nutt, K. Demyttenaere, Z. Janka, T. Aarre, M. Bourin, P. L. Canonico, J. L. Carrasco, and S. Stahl
The other face of depression, reduced positive affect: the role of catecholamines in causation and cure
J Psychopharmacol, July 1, 2007; 21(5): 461 - 471.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
S. H. Kennedy, J. Z. Konarski, Z. V. Segal, M. A. Lau, P. J. Bieling, R. S. McIntyre, and H. S. Mayberg
Differences in Brain Glucose Metabolism Between Responders to CBT and Venlafaxine in a 16-Week Randomized Controlled Trial
Am J Psychiatry, May 1, 2007; 164(5): 778 - 788.
[Abstract] [Full Text] [PDF]

Home page
 APPI Online CMEHome page
References
PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2.
[Full Text]

Home page
 Journal of Pharmacy PracticeHome page
M. J. Ehret
Pharmacogenomics of Antidepressant Medications
Journal of Pharmacy Practice, December 1, 2006; 19(6): 342 - 352.
[Abstract] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
M. J. Ehret and B. Chavez
A Review of the STAR*D Trial
Journal of Pharmacy Practice, December 1, 2006; 19(6): 353 - 360.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
M. L. Furey and W. C. Drevets
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
Arch Gen Psychiatry, October 1, 2006; 63(10): 1121 - 1129.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. Davidson, D. Baldwin, D. J. Stein, E. Kuper, I. Benattia, S. Ahmed, R. Pedersen, and J. Musgnung
Treatment of Posttraumatic Stress Disorder With Venlafaxine Extended Release: A 6-Month Randomized Controlled Trial.
Arch Gen Psychiatry, October 1, 2006; 63(10): 1158 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
D. Taylor and J R. Scott
Volte-faceon venlafaxine - reasons and reflections
J Psychopharmacol, September 1, 2006; 20(5): 597 - 601.
[PDF]

Home page
 Br. J. PsychiatryHome page
R. M. Post, L. L. Altshuler, G. S. Leverich, M. A. Frye, W. A. Nolen, R. W. Kupka, T. Suppes, S. McElroy, P. E. Keck, K. D. Denicoff, et al.
Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline
The British Journal of Psychiatry, August 1, 2006; 189(2): 124 - 131.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
N. Sussman, S. C. Williams, L. Tebartz van Elst, D. Ebert, B. Hesslinger, A. J. Rush, M. H. Trivedi, S. R. Wisniewski, the STAR*D trial investigators, and D. R. Rubinow
Depression--augmentation or switch after initial SSRI treatment.
N. Engl. J. Med., June 15, 2006; 354(24): 2611 - 2613.
[Full Text] [PDF]

Home page
 J PsychopharmacolHome page
J. E. Alpert
Improving depression outcome: new concepts, strategies and technologies
J Psychopharmacol, May 1, 2006; 20(3_suppl): 3 - 4.
[PDF]

Home page
 J PsychopharmacolHome page
C. DeBattista
Augmentation and combination strategies for depression
J Psychopharmacol, May 1, 2006; 20(3_suppl): 11 - 18.
[Abstract] [PDF]

Home page
 Br. J. PsychiatryHome page
D. G. PERAHIA, I. GILABERTE, F. WANG, C. G. WILTSE, S. A. HUCKINS, J. W. CLEMENS, S. A. MONTGOMERY, A. L. MONTEJO, and M. J. DETKE
Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study
The British Journal of Psychiatry, April 1, 2006; 188(4): 346 - 353.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. J. Rush, M. H. Trivedi, S. R. Wisniewski, J. W. Stewart, A. A. Nierenberg, M. E. Thase, L. Ritz, M. M. Biggs, D. Warden, J. F. Luther, et al.
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
N. Engl. J. Med., March 23, 2006; 354(12): 1231 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. Botts
Moving beyond balance for a better antidepressant
Am. J. Health Syst. Pharm., December 1, 2005; 62(23): 2479 - 2479.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
A. D. Westanmo, J. Gayken, and R. Haight
Duloxetine: A balanced and selective norepinephrine- and serotonin-reuptake inhibitor
Am. J. Health Syst. Pharm., December 1, 2005; 62(23): 2481 - 2490.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
P. M. Vis, M. van Baardewijk, and T. R Einarson
Duloxetine and Venlafaxine-XR in the Treatment of Major Depressive Disorder: A Meta-Analysis of Randomized Clinical Trials
Ann. Pharmacother., November 1, 2005; 39(11): 1798 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. J. Mann
The medical management of depression.
N. Engl. J. Med., October 27, 2005; 353(17): 1819 - 1834.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. A. Hansen, G. Gartlehner, K. N. Lohr, B. N. Gaynes, and T. S. Carey
Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder
Ann Intern Med, September 20, 2005; 143(6): 415 - 426.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
M. P. Fleck and E. Horwath
Pharmacologic Management of Difficult-to-Treat Depression in Clinical Practice
Psychiatr Serv, August 1, 2005; 56(8): 1005 - 1011.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. Chou and M. Helfand
Challenges in Systematic Reviews That Assess Treatment Harms
Ann Intern Med, June 21, 2005; 142(12_Part_2): 1090 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
G. S. Alexopoulos, I. R. Katz, M. L. Bruce, M. Heo, T. T. Have, P. Raue, H. R. Bogner, H. C. Schulberg, B. H. Mulsant, C. F. Reynolds III, et al.
Remission in Depressed Geriatric Primary Care Patients: A Report From the PROSPECT Study
Am J Psychiatry, April 1, 2005; 162(4): 718 - 724.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
A. A. Nierenberg, P. Eidelman, Y. Wu, and M. Joseph
Depression: An Update for the Clinician
Focus, January 1, 2005; 3(1): 3 - 12.
[Full Text] [PDF]

Home page
 FocusHome page
L. J. Fochtmann and A. J. Gelenberg
Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition
Focus, January 1, 2005; 3(1): 34 - 42.
[Full Text] [PDF]

Home page
 FocusHome page
R. D. Jindal and M. E. Thase
Integrating Psychotherapy and Pharmacotherapy to Improve Outcomes Among Patients With Mood Disorders
Focus, January 1, 2005; 3(1): 114 - 121.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
C. B. Nemeroff, C. M. Heim, M. E. Thase, D. N. Klein, A. J. Rush, A. F. Schatzberg, P. T. Ninan, J. P. McCullough Jr., P. M. Weiss, D. L. Dunner, et al.
Differential Responses to Psychotherapy Versus Pharmacotherapy in Patients With Chronic Forms of Major Depression and Childhood Trauma
Focus, January 1, 2005; 3(1): 131 - 135.
[Abstract] [Full Text] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
D. P. Devanand, N. Juszczak, M. S. Nobler, N. Turret, L. Fitzsimons, H. A. Sackeim, and S. P. Roose
An Open Treatment Trial of Venlafaxine for Elderly Patients With Dysthymic Disorder
J Geriatr Psychiatry Neurol, December 1, 2004; 17(4): 219 - 224.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
P. A. Pirraglia, A. B. Rosen, R. C. Hermann, N. V. Olchanski, and P. Neumann
Cost-Utility Analysis Studies of Depression Management: A Systematic Review
Am J Psychiatry, December 1, 2004; 161(12): 2155 - 2162.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
P. K. Corey-Lisle, R. Nash, P. Stang, and R. Swindle
Response, Partial Response, and Nonresponse in Primary Care Treatment of Depression
Arch Intern Med, June 14, 2004; 164(11): 1197 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
L. Trick, N. Stanley, U. Rigney, and I. Hindmarch
A Double-Blind, Randomized, 26-Week Study Comparing the Cognitive and Psychomotor Effects and Efficacy of 75 mg (37.5 mg b.i.d.) Venlafaxine and 75 mg (25 mg Mane, 50 mg Nocte) Dothiepin in Elderly Patients with Moderate Major Depression Being Treated in General Practice
J Psychopharmacol, June 1, 2004; 18(2): 205 - 214.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
J. H. Meyer, A. A. Wilson, S. Sagrati, D. Hussey, A. Carella, W. Z. Potter, N. Ginovart, E. P. Spencer, A. Cheok, and S. Houle
Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study
Am J Psychiatry, May 1, 2004; 161(5): 826 - 835.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
H. Kavirajan
Venlafaxine and SSRI remission data revisited
The British Journal of Psychiatry, May 1, 2004; 184(5): 452 - 453.
[Full Text] [PDF]

Home page
 Social Studies of ScienceHome page
D. Healy
Shaping the Intimate:: Influences on the Experience of Everyday Nerves
Social Studies of Science, April 1, 2004; 34(2): 219 - 245.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. B. Nemeroff, C. M. Heim, M. E. Thase, D. N. Klein, A. J. Rush, A. F. Schatzberg, P. T. Ninan, J. P. McCullough Jr., P. M. Weiss, D. L. Dunner, et al.
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma
PNAS, November 25, 2003; 100(24): 14293 - 14296.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
R. D. Jindal and M. E. Thase
Integration of Care: Integrating Psychotherapy and Pharmacotherapy to Improve Outcomes Among Patients With Mood Disorders
Psychiatr Serv, November 1, 2003; 54(11): 1484 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
I. M. Anderson
Drug treatment of depression: reflections on the evidence
Adv. Psychiatr. Treat., January 1, 2003; 9(1): 11 - 20.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
M. L. Gilmor, M. J. Owens, and C. B. Nemeroff
Inhibition of Norepinephrine Uptake in Patients With Major Depression Treated With Paroxetine
Am J Psychiatry, October 1, 2002; 159(10): 1702 - 1710.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
C. E. Beyer, S. Boikess, B. Luo, and L. A. Dawson
Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study
J Psychopharmacol, July 1, 2002; 16(4): 297 - 304.
[Abstract] [PDF]

Home page
 Br. J. PsychiatryHome page
D. SMITH, C. DEMPSTER, J. GLANVILLE, N. FREEMANTLE, and I. ANDERSON
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis
The British Journal of Psychiatry, May 1, 2002; 180(5): 396 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
I. C. Wright, M. E. Thase, G. Jackson, T. Brown, J. Butler, P. Cowen, C. Freeman, H. Freeman, L. Gask, G. Kassianos, et al.
Conflict of interest and the British Journal of Psychiatry Author's reply Response from Neurolink Editor's response
The British Journal of Psychiatry, January 1, 2002; 180(1): 82 - 83.
[Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
R. C. Shelton and A. J. Tomarken
Can Recovery From Depression Be Achieved?
Psychiatr Serv, November 1, 2001; 52(11): 1469 - 1478.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
J. Warner
Quality of evidence in meta-analysis
The British Journal of Psychiatry, July 1, 2001; 179 (1): 79 - 79.
[Full Text]

Home page
 JAMAHome page
R. Abrams, P. M. Doraiswamy, A. C. Scates, and H. A. Sackeim
Relapse of Depression After Electroconvulsive Therapy
JAMA, June 27, 2001; 285(24): 3087 - 3089.
[Full Text] [PDF]

Home page
 JWatch Women's HealthHome page
Curing Depression: Is Venlafaxine Best?
Journal Watch Women's Health, April 17, 2001; 2001(417): 7 - 7.
[Full Text]

Home page
 JWatch PsychiatryHome page
Remission of Depression Greater on Venlafaxine than SSRIs
Journal Watch Psychiatry, March 22, 2001; 2001(322): 8 - 8.
[Full Text]

Home page
 Br Med BullHome page
I. M Anderson
Meta-analytical studies on new antidepressants
Br. Med. Bull., March 1, 2001; 57(1): 161 - 178.
[Abstract] [Full Text] [PDF]